cAMP-specific 3',5'-cyclic phosphodiesterase 4B is an enzyme that in humans is encoded by the PDE4B gene. [5] This gene is a member of the type IV, cyclic AMP (cAMP)-specific, cyclic nucleotide phosphodiesterase (PDE) family.

2024年12月25日 · PDE4B (Phosphodiesterase 4B) is a Protein Coding gene. Diseases associated with PDE4B include Autism Spectrum Disorder and Ocular Hypotension. Among its related pathways are GPCR downstream signalling and Sweet Taste Signaling. Gene Ontology (GO) annotations related to this gene include transmembrane transporter …

2024年9月17日 · Nerandomilast为一款选择性的PDE4B抑制剂，具有独特的作用机制，在抗炎症、抗纤维化方面发挥重要作用。 总结. Nerandomilast此次成功意味着十年来第一个获得成功的IPF三期临床试验，有望为广大IPF患者带来全新的治疗选择。 Armstrong技术全梳理系列. GPRC5D靶点全梳理；

该基因是 IV 型环磷酸二酯酶 (cAMP) 特异性环核苷酸磷酸二酯酶 (PDE) 家族的成员。 编码的蛋白质调节环核苷酸的细胞浓度，从而在信号转导中发挥作用。 这种蛋白质的活性改变与精神分裂症和双相情感障碍有关。 可变剪接和替代启动子的使用导致编码不同亚型的多个转录变体。 [RefSeq 提供，2014 年 7 月] This gene is a member of the type IV, cyclic AMP (cAMP)-specific, cyclic nucleotide phosphodiesterase (PDE) family.

2020年5月19日 · However, we evaluate the evidence, which suggests the activity from a sub-family of the PDE4 family, namely PDE4B, underpins a range of important functions in the brain that positions the PDE4B enzymes as a therapeutic target for a diverse collection of indications, such as, schizophrenia, neuroinflammation, and cognitive function.

2024年3月23日 · Meta-analysis of genome-wide association study data has implicated PDE4B in the pathogenesis of Alzheimer’s disease (AD), the leading cause of senile dementia. PDE4B encodes one of four...

PDE4B expression was reduced in advanced prostate cancer and PDE4B knockdown promoted castration-resistant growth of LNCaP cells. The reported anti-inflammatory activity of bresol might be attributed to its abilities to inhibit PDE4B and thus elevate cAMP levels in human monocytes.

勃林格殷格翰在肺纤维化性疾病领域具备丰富积淀的研发实力：除去这款在研 pde4b抑制剂 ，已有特发性肺纤维化（ipf）治疗药物—ofev®（尼达尼布）获批上市，尽管并不认为能够逆转疾病进程，这款产品2021年销售额由21亿欧元上涨至25亿欧元（27亿美元）。

PDE4B may be characterized as a secondary PRP due to modulation of cAMP levels that promote the process through initial to late stage. As such PDE4B would function to modulate the synaptic plasticity stimuli within the cell and allow for the change in reaction later in the memory forming process .

2022年10月25日 · 近日，中国国家药品监督管理局（NMPA）药品审评中心（CDE）官网公示，勃林格殷格翰（Boehringer Ingelheim）申报的磷酸二酯酶4B（PDE4B）选择性抑制剂BI 1015550片获得批准开展两项Ⅲ 期临床试验[1]，拟开发适应症分别为特发性肺纤维化（Idiopathic Pulmonary Fibrosis, IPF）以及进行性纤维化性间质性肺疾病（Progressive Fibrosing Interstitial Lung Diseases, PF-ILD）。 BI 1015550 的Ⅲ期临床试验中国地区将与全球同步进行并由中国医学科 …